help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mandel, S.
Right arrow Articles by Lafranchi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mandel, S.
Right arrow Articles by Lafranchi, S.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 190-194, Copyright © 1995 by Endocrine Society


ARTICLES

Changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment

S Mandel, E Moreland, V Nichols, C Hanna and S Lafranchi
Department of Pediatrics, Oregon Health Sciences University, Portland 97201.

To assess the relative determinants of growth rate, we measured serum levels of insulin-like growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and GH-binding protein (GHBP) as well as IGF-I erythrocyte receptor specific binding (SB) in 14 prepubertal GH-deficient children before and during the first year of treatment with 0.043 mg/kg.day GH. Serum IGF-I and IGFBP-3 levels, measured by RIA, were significantly increased by 2 weeks and showed progressive increases throughout the year of GH therapy. Growth rate (height velocity SD score adjusted for bone age) correlated best with the 12 month changes in IGFBP-3 (r = 0.81; P < 0.001) and IGF-I (r = 0.72; P = 0.005), and to a lesser extent with the 12 month absolute IGFBP-3 (r = 0.58; P = 0.04) and the 6 month change in IGFBP-3 (r = 0.55; P = 0.05). The baseline IGF-I correlated inversely with the growth rate during GH therapy (r = -0.55; P = 0.05) and was the best pretreatment predictor of growth response. GHBP, as measured by ligand-mediated immunofunctional assay, showed no significant change during GH therapy and did not correlate with growth response. The baseline GHBP, however, did correlate with both the 12 month IGFBP-3 (r = 0.72; P = 0.006) as well as the 2 week change in IGFBP-3 (r = 0.63; P = 0.05). Erythrocyte IGF-I SB showed a significant decrease by 6 months secondary to a decrease in IGF-I receptor number, with no change in affinity. The 6 month IGF-I receptor binding correlated inversely with the increase in IGF-I (r = -0.88; P < 0.001). Erythrocyte IGF-I SB at baseline did not correlate with the growth response, although there was an inverse trend between the 6 month IGF-I receptor level and the growth rate. IGF-I and IGFBP-3 show progressive increases, whereas the erythrocyte IGF-I receptor-binding capacity decreases by 6 months, and GHBP shows little change during the first year of GH treatment. Data from this study suggest that changes in IGFBP-3 and, to a lesser extent, IGF-I are the major correlates of growth rate, and that down-regulation of the IGF-I receptor may have relatively little influence on growth rate compared with changes in IGFBP-3 and IGF-I.


This article has been cited by other articles:


Home page
Toxicol SciHome page
G. M. Farris, G. K. Miller, G. K. Wollenberg, S. Molon-Noblot, C. Chan, and S. Prahalada
Recombinant Rat and Mouse Growth Hormones: Risk Assessment of Carcinogenic Potential in 2-Year Bioassays in Rats and Mice
Toxicol. Sci., June 1, 2007; 97(2): 548 - 561.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman
Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men
Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Endocr. Rev., February 1, 2005; 26(1): 114 - 146.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
K. E. Govoni, T. A. Hoagland, and S. A. Zinn
The ontogeny of the somatotropic axis in Hereford calves from birth to one year of age and its response to administration of exogenous bovine somatotropin
J Anim Sci, June 1, 2004; 82(6): 1646 - 1655.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Ducos, S. Cabrol, M. Houang, L. Perin, M. Holzenberger, and Y. Le Bouc
IGF Type 1 Receptor Ligand Binding Characteristics Are Altered in a Subgroup of Children with Intrauterine Growth Retardation
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5516 - 5524.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Deal, J. Ma, F. Wilkin, J. Paquette, F. Rozen, B. Ge, T. Hudson, M. Stampfer, and M. Pollak
Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1274 - 1280.
[Abstract] [Full Text]


Home page
PediatricsHome page
E. M. W. Duff, N. M. Anderson, and E. S. Cooper
Plasma Insulin-like Growth Factor-1, Type 1 Procollagen, and Serum Tumor Necrosis Factor alpha  in Children Recovering From Trichuris Dysentery Syndrome
Pediatrics, May 1, 1999; 103(5): 69e - 69.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Olivecrona, A. Hilding, C. Ekström, H. Barle, B. Nyberg, C. Möller, P. J. Delhanty, R. C. Baxter, B. Angelin, T. J. Ekström, et al.
Acute and Short-Term Effects of Growth Hormone on Insulin-Like Growth Factors and Their Binding Proteins: Serum Levels and Hepatic Messenger Ribonucleic Acid Responses in Humans
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 553 - 560.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Kawai, S. Kanzaki, S. Takano-Watou, C. Tada, Y. Yamanaka, T. Miyata, M. Oka, and Y. Seino
Serum Free Insulin-Like Growth Factor I (IGF-I), Total IGF-I, and IGF-Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 82 - 89.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. E. Wilson
Effects of Estradiol and Exogenous Insulin-Like Growth Factor I (IGF-I) on the IGF-I Axis during Growth Hormone Inhibition and Antagonism
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4013 - 4021.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg
Growth Hormone and Bone
Endocr. Rev., February 1, 1998; 19(1): 55 - 79.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
S. Rajaram, D. J. Baylink, and S. Mohan
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions
Endocr. Rev., December 1, 1997; 18(6): 801 - 831.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
P. D. K. Lee, S. K. Durham, V. Martinez, O. Vasconez, D. R. Powell, and J. Guevara-Aguirre
Kinetics of Insulin-Like Growth Factor (IGF) and IGF-Binding Protein Responses to a Single Dose of Growth Hormone
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2266 - 2274.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society